What Genetic Testing of Embryos Costs to Add On

What PGT-A Adds to the Bill

PGT-A typically adds $2,000 to $3,000 as a base laboratory fee for a single IVF cycle, plus $200 to $600 per embryo biopsied and sent for analysis, so the total scales with how many embryos make it to the blastocyst stage. A cycle that produces six biopsy-worthy embryos costs meaningfully more to test than one that produces two, which is one reason a PGT-A quote is best requested as a per-embryo rate rather than a single flat number.

That fee sits separate from, and on top of, the base IVF cycle charge, and it typically does not include what happens after testing: embryo storage while results come back, and a later frozen embryo transfer once a euploid embryo is identified.

Why the Price Has Two Separate Parts

The PGT-A charge is really two fees bundled into one quote: an embryology-lab fee for biopsying a few cells from each embryo, and a genetics-lab fee for the chromosomal analysis itself, which is often outsourced to a separate reference laboratory rather than performed on-site. Clinics vary in whether they mark up the outside lab's charge or pass it through directly, which is part of why the same test can be quoted at noticeably different prices between two clinics.

Asking a clinic to itemize the biopsy fee separately from the genetic-analysis fee makes it possible to see which part of the total is the clinic's own charge and which part is a pass-through cost set by the testing lab.

PGT-A Requires ICSI, Which Is Its Own Added Cost

Most labs pair PGT-A with ICSI fertilization rather than conventional insemination, since injecting a single sperm directly into each egg reduces the chance that leftover sperm material on the outside of the embryo affects the small tissue sample taken for testing. Current professional guidance recognizes planned genetic testing as one of the legitimate reasons to add ICSI to a cycle, distinct from applying it as an unindicated default across every patient 1Ref 1Practice Committees of ASRM and SART (2026).Intracytoplasmic sperm injection for nonmale factor indications: a committee opinion.That planned PGT is a recognized indication for adding ICSI to a cycle, distinct from applying ICSI as an unindicated default..

That pairing means a PGT-A quote is rarely just the PGT-A fee — it usually assumes an ICSI fee is already part of the total, which is worth confirming explicitly if a clinic's estimate doesn't spell it out.

What the Evidence Says PGT-A Actually Buys

Current professional guidance is direct about what PGT-A has and hasn't been shown to do: its value as a routine screen added to every IVF cycle has not been demonstrated, and recent multicenter randomized trials found broadly similar overall pregnancy outcomes with PGT-A compared with cycles that didn't use it 2Ref 2Practice Committees of ASRM and SART (2024).The use of preimplantation genetic testing for aneuploidy: a committee opinion.That the value of PGT-A as a routine screen for all IVF patients has not been demonstrated, and that recent multicenter trials found broadly similar pregnancy outcomes with and without it.. One of those trials, a multicenter study of good-prognosis patients, found PGT-A did not improve the ongoing-pregnancy rate compared with selecting embryos by appearance alone under a microscope 3Ref 3Munné S, et al. (STAR Study Group) (2019).Preimplantation genetic testing for aneuploidy versus morphology as selection criteria for single frozen-thawed embryo transfer in good-prognosis patients: a multicenter randomized clinical trial.That in a multicenter RCT of good-prognosis patients, PGT-A did not improve the ongoing-pregnancy rate compared with selecting embryos by morphology alone..

A national regulator that grades the evidence behind common IVF add-ons rates PGT-A among the add-ons lacking good evidence of improving the live-birth rate for a typical patient 4Ref 4Human Fertilisation and Embryology Authority (2024).Treatment add-ons with limited evidence.That a regulator's evidence-rating system rates PGT-A among the IVF add-ons lacking good evidence of improving the live-birth rate for a typical patient.. None of that means PGT-A does nothing — what is PGT-A genetic testing of embryos and whether pgt-a effectiveness holds up for a specific situation are questions worth reading into more deeply before paying for it, since the honest picture is more nuanced than either a marketing pitch or a blanket dismissal.

The Follow-On Costs: Storage and the Frozen Transfer

Because PGT-A results take roughly one to two weeks, almost every biopsied embryo is frozen rather than transferred fresh, which means a PGT-A cycle converts into two separate follow-on bills: embryo storage fees while the embryos wait, and a later frozen transfer, or FET cost, once a euploid embryo is chosen. Neither of those charges is part of the PGT-A fee itself, even though PGT-A is the reason both are happening on this particular timeline.

Storage is typically billed annually or in shorter blocks, and it continues for as long as untested or untransferred embryos remain frozen, which is worth budgeting for beyond just the immediate testing cost.

How PGT-A Differs in Price From PGT-M and PGT-SR

PGT-A screens for the correct number of chromosomes and is priced as a standardized per-embryo test, while pgt-m testing for a specific inherited single-gene condition, or PGT-SR for a known structural chromosomal rearrangement, requires custom probe development for that family's specific mutation before testing can even begin. That development step is a separate, often substantial upfront fee that PGT-A does not carry, which is why a couple testing for a known genetic condition should expect a meaningfully different total than a couple doing routine aneuploidy screening alone.

A clinic quoting a single flat "genetic testing" price without specifying which of these three tests it means is a sign to ask for clarification before assuming PGT-A pricing applies.

Timing differs too: probe development for PGT-M or PGT-SR can take several weeks before the first embryo is ever biopsied, which is worth planning around well ahead of a retrieval, while PGT-A's standardized process typically starts as soon as embryos reach the blastocyst stage with no comparable lead time.

A Realistic Total for Adding PGT-A to a Cycle

Adding up the biopsy and analysis fee, the ICSI fee it typically requires, and the storage and frozen-transfer costs that follow, PGT-A commonly adds $5,000 to $8,000 to the total cost of one IVF cycle once every downstream piece is counted, not just the standalone testing fee. That is a significant addition on top of costs that are already substantial for most patients paying out of pocket at any stage of infertility care 5Ref 5Katz P, Showstack J, Smith JF, et al. (2011).Costs of infertility treatment: results from an 18-month prospective cohort study.That real-world out-of-pocket infertility costs are already substantial for most patients before an add-on like PGT-A is included..

The clearest financial argument for PGT-A is indirect: transferring a single embryo already known to carry the correct chromosome number lowers the odds of a multiple-gestation pregnancy, which itself carries higher medical risk and cost than a singleton pregnancy 6Ref 6Practice Committee of ASRM and SART (2022).Multiple gestation associated with infertility therapy: a committee opinion.That multiple gestation carries higher maternal and neonatal risk and cost than a singleton pregnancy, and that elective single-embryo transfer reduces that risk — the indirect financial argument for PGT-A.. Whether that trade-off is worth the added testing cost for a specific patient depends on age, embryo count, and how much certainty is worth paying for — not a single right answer for everyone.